SOURCE: Clearant, Inc.

May 12, 2008 18:59 ET

Clearant, Inc. Reports Record Preliminary 1st Quarter 2008 Revenue Results

1st Quarter Revenue Increases 46% vs 4th Quarter Results

LOS ANGELES, CA--(Marketwire - May 12, 2008) - Clearant, Inc. (OTCBB: CLRA), owner of the Clearant Process® designed to substantially reduce all types of pathogens in biological products including HIV, today announced that preliminary revenues for the 1st quarter period ending March 31, 2008 increased 46% to $0.47 million compared to $0.32 million in the 4th quarter 2007.

Preliminary direct distribution revenue grew to a record $0.31 million for the 1st quarter of 2008 compared to $0.26 million in the 4th quarter of 2007, a 19% increase. Preliminary revenues from licensing, fee for service, and contract research, activities increased to $158,000 in the 1st quarter 2008 compared to $65,000 in the 4th quarter 2007.

Clearant will provide more detailed information about its first quarter 2008 results after filing its Quarterly Report due on May 15, 2008.

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process®, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. The Company has distributed implants sterilized by the Clearant Process® directly to surgeons, hospitals and clinics since June 2006. In addition, Clearant licenses the Clearant Process®, and provides its patented sterilization services, to tissue banks and other biological products manufacturers. To date more than 8,000 patients have been successfully implanted with Clearant Process® sterile implants supplied by one of the Company's licensed partners. The Clearant Process®, unlike its various competitors, is applied in the final packaging and reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. For more information, please visit

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at

Contact Information

  • Contact:
    Clearant, Inc.
    Jon Garfield
    Chief Executive Officer